Supernus (SUPN) AI Analysis

SUPN$29.72+0.52 +1.78%
Drug Manufacturers - Specialty & GenericGrowth Stock
Compare
Market cap$1.73BEnterprise value$1.72BRevenue (TTM)$1.37BMarket position—

Score

59
Neutral
Value
57
Quality
35
Growth
86

Supernus mixes growth with a still-reasonable multiple — Growth 86/100 with P/E 7.1, about 67% below its own multi-year median. Under the hood: P/E 7.1, about 67% below its own multi-year median, plus revenue compounding ~11% annually over recent years. Street targets still imply ~60% upside.

Supernus (SUPN) AI Analysis

SUPN price $29.72 +0.52 +1.78%

Ticker
SUPN
Price
$29.72
Change
+0.52 +1.78%
Market cap
$1.73B
P/E
7.79
Forward P/E
13.26
Dividend yield
0.31%
Beta
0.52
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stocklytics score
59
Value
57
Quality
35
Growth
86

Stocklytics score rationale: value 57, quality 35, growth 86.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener